Thomas Borody is an Australian gastoenterologist based in Sydney who is noted for his work in novel therapies for gastrointestinal disorders. For a topic outline on this subject see List of basic Australia topics. Gastroenterology ( MeSH heading is the branch of Medicine whereby the Digestive system and its disorders are studied Sydney (ˈsɪdniː is the most populous city in Australia, with a Metropolitan area population of approximately 4
Contents |
Life
Borody was born in Poland and came to Australia with his family in 1960. He gained degrees in Science and Medicine from the University of New South Wales in the mid-1970s and then worked for nine years at St Vincent's Hospital in Sydney before understaking postgraduate research at Sydney's Garvan Institute of Medical Research and at the Mayo Clinic. The University of New South Wales, also known as UNSW or colloquially as New South, is a University situated in Kensington, a suburb in Mayo Clinic is a Non-profit medical practice Its headquarters the Mayo Medical School and its research facilities are in Rochester Minnesota in He gained his Doctorate in Medicine in 1984.
Triple therapy for H. pylori infection
As a gastroenterologist, Borody is most famous for his development of the triple therapy for infection with Helicobacter pylori bacteria. An infection is the detrimental Colonization of a host Organism by a foreign Species. Helicobacter pylori ( is a Gram-negative, microaerophilic Bacterium that inhabits various areas of the stomach and Duodenum. The Bacteria ( singular: bacterium) are a large group of unicellular Microorganisms Typically a few Micrometres in length bacteria have The triple therapy, which was invented around 1987, is a combination of bismuth, metronidazole and tetracycline. Bismuth (ˈbɪzməθ is a Chemical element that has the symbol Bi and Atomic number 83 Metronidazole ( INN) (mɛtrəˈnaɪdəzoʊl is a Nitroimidazole anti-infective medication used mainly in the treatment of infections caused by susceptible This article deals with the specific antibiotic called tetracycline .
Subsequent career
In the 1990s and early 2000s Borody discovered a number of other drug combinations which have been demonstrated to be important in treating gastrointestinal disorders such as Crohn's disease. Crohn's disease is a Disease of the Digestive system which may affect any part of the Gastrointestinal tract from Mouth to Anus Dr. Borody has also pioneered an innovative treatment for Pseudomembranous colitis and Ulcerative colitis called Fecal bacteriotherapy which involves repopulating the gut with beneficial bacteria using fecal material from healthy individuals. Clostridium difficile Pseudomembranous colitis is an infection of the colon often but not always caused by the Bacterium Clostridium difficile Ulcerative colitis ( Colitis ulcerosa, UC) is a form of Inflammatory bowel disease (IBD Fecal bacteriotherapy, also known as fecal transfusion, fecal transplant, or human probiotic infusion (HPI is a medical treatment for patients with
Current work
Borody currently operates a Sydney-based clinic focused on gastrointestinal disorders called the Centre for Digestive Diseases. In 2004 he became a founder of the Australian biotechnology company Giaconda, of which he remains the largest shareholder. Giaconda is an Australian Biotechnology company headquartered in Sydney.
External links
Dapyx Software network: MP3 Explorer | Ebook Manager | Zenithic